GlassScriptPhysician profile
Admassu Hailu
NPI 1831157825
$6,314.29
in general payments reported to CMS, 2019-2025
30 companies · $1,370 in 2025
The $1,370 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $358 · 2021: $426 · 2022: $468 · 2023: $1,472 · 2024: $1,443 · 2025: $1,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,284.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,271.30 | 2019-2025 | |
| Pfizer INC. | $902.52 | 2019-2025 | |
| Amgen INC. | $447.67 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $437.11 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Merck Sharp & Dohme LLC | $421.71 | 2022-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $356.97 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.51 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $297.23 | 2019-2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $295.94 | 2024 | Arcalyst |
| Abbott Laboratories | $194.50 | 2021-2023 | Cardiomems |
| Scpharmaceuticals INC. | $174.48 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $133.23 | 2019-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $127.87 | 2021-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $124.96 | 2021-2025 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $114.94 | 2020-2025 | Camzyos, Eliquis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $110.50 | 2023-2025 | |
| Abiomed | $101.23 | 2024 | Impella |
| Esperion Therapeutics, INC. | $101.08 | 2021-2022 | |
| Bridgebio Pharma, INC. | $86.00 | 2025 | Attruby |
| Amarin Pharma, INC. | $60.71 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $40.93 | 2023-2025 | Definity |
| Lexicon Pharmaceuticals, INC. | $32.75 | 2023 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $28.55 | 2021 | |
| Genzyme Corporation | $25.68 | 2025 | |
| Edwards Lifesciences Corporation | $24.86 | 2025 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $21.18 | 2023 | |
| Zimmer Biomet Holdings, INC. | $19.57 | 2020 | |
| Lilly USA, LLC | $16.98 | 2024 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $14.48 | 2019 | |
| Gilead Sciences, INC. | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Admassu Hailu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.